We have examined the effects of the selective 5-HT 1a and 5-HT 1b agonists 8-hydroxy-2-(di-npropylamino)tetralin (8-OHDPAT) and 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline (CGS12066b), respectively on erection in rats in vivo and rabbit corpus cavernosum 
Introduction
The role of serotonin (5-HT) in sexual function has historically been described as inhibitory in nature. 1 An abundance of early work demonstrated that reduction in brain levels of 5-HT were associated with a facilitation of sexual behavior in most species studied whereas an increase in brain 5-HT levels reduced sexual behavior. 2 -4 However more recent work has shown that such a simple scheme may not account for the complex effects that 5-HT exerts on different aspects of sexual behavior via activation of numerous 5-HT receptor types and subtypes at both spinal and supraspinal levels. 5 -7 The effects of 5-HT ligands on erection in male rats vary depending on the location, type and subtype of the 5-HT receptor involved in the response. Systemically or centrally administered 5-HT 1a , and 5-HT 1b agonists do not elicit erection in rats 8 and 5-HT 1a agonists and antagonists administered systemically and centrally can attenuate erection induced by dopaminergic agonists. 9, 10 Less is known about the actions of 5-HT 1b agonists and antagonists on erection elicited by central dopaminergic mechanisms. Peripherally 5-HT inhibits increases in intracavernosal pressure resulting from electrical stimulation of the sacral spinal cord, an effect believed to be mediated by 5-HT 1d receptors. 11 However 5-HT and the non-selective selective 5-HT agonist m-CPP both cause activation of peripheral pre-ganglionic neurons resulting in increases in intracavernosal pressure which are temporally related to activity in the cavernous nerve. 6 The mechanisms responsible for these diverse central and peripheral actions have not yet been fully elucidated. m-CPP elicits erection in conscious rats via activation of 5-HT 2c receptors 12 whereas the receptor(s) mediating the effects of m-CPP on ICP responses in anesthetized rats have not been elucidated. While some of the 5-HT agonists inhibit erectile function they can also enhance ejaculation and copulatory performance. 13, 14 The aim of the present study was to assess the effects of selective 5-HT 1 agonists on: (a) apomorphine induced erection; (b) cavernous nerve activity and intracavernous pressure responses caused by direct nerve stimulation and m-CPP administration; and (c) responses of corporal smooth muscle stimulated in vitro.
Materials and methods
All experiments were approved by the animal use and care committee of the National University of Singapore.
Apomorphine induced erection in rats in vivo
Male Sprague-Dawley rats (300 -500 g) were housed in groups of five under 12 h light=dark cycle (lights off 09:00 to 21:00) at ambient temperature with unlimited access to food and water. One hour prior to the start of experiments rats were transferred to an observation room maintained at 22 C. After 1 h rats were injected via an intraperitoneal route (i.p.) with vehicle (two groups; n ¼ 8 per group), 8-OHDPAT (0.04, 0.16 or 0.64 mg=kg; n ¼ 8 per dose) or CGS12066b (1.0, 3.0, or 10.0 mg=kg; n ¼ 8 per dose) followed 15 min later by subcutaneous (s.c.) apomorphine (0.1 mg=kg) or vehicle administration. All drugs were administered in a volume of 1.0 ml=kg. Five minutes after apomorphine or vehicle administration rats were placed in a clear Plexiglas 1 cage for observation of erectile responses for 30 min. Erections were monitored according to methods described previously. 15 Briefly, erections were scored for rats exhibiting an abrupt upright posture with pelvic thrusting and an engorged penis.
Cavernous nerve and intracavernosal pressure responses in rats in vivo
Male Sprague-Dawley rats (300 -500 g) were anaesthetized with sodium pentobarbitone (65 mg=kg; i.p.) and prepared by cannulation (PE 50 Tubing) of the external jugular vein and common carotid artery for drug administration and blood pressure monitoring respectively. The trachea was cannulated (14 G Jelco catheter) for ventilation (Harvard respirator) at a volume of 10 ml=kg and a rate of 60 strokes=min. The lateral prostate was exposed through a midline incision and the cavernous nerve was gently dissected free and suspended on platinum wire electrodes (1 mm interelectrode distance) for stimulation and recording purposes. A 27 gauge needle filled with heparinized saline (100 i.u.=ml) was placed in the penile crus for recording intracavernous pressure responses to nerve stimulation and drug administration. 
Cavernosum smooth muscle in vivo
Male New Zealand White rabbits (3 -4 kg) were exanguinated with CO 2 followed immediately by penectomy. The corpus cavernosum (CC) smooth muscle was dissected free from the tunica albuginea and suspended in 25 ml organ baths, under a resting tension of 1 g, in Carbogen 1 gassed Krebs-Henseleit buffer. Strips were washed three times during a 1 h To test the effects of 8-OHDPAT on NANC mediated relaxation responses to submaximal field stimulation, CC strips were first contracted with 3 6 10 75 M NA in the presence of 1.0 mM atropine and 2.0 mM guanethidine. Five minutes later CC strips were stimulated three times, at 8 Hz, at 2 min intervals before incubation with 10 78 -10 74 M 8-OHDPAT for 2 min. Following incubation CC strips were again stimulated three times at 2 min intervals. The average response to three stimulations before and after drug treatment were calculated for each strip. To assess the effects of CGS12066b on NANC mediated relaxation, atropine and guanethidine treated CC strips were precontracted with 3 6 10 75 M NA for 5 min prior to the addition of saline or CGS12066b (10 76 M). Two minutes after addition of test agent full frequency -response curves (FRCs) were constructed. In all cases relaxation responses were calculated as a percentage of the maximal response to 128 Hz stimulation in pre-drug FRCs.
Solutions and drugs
Solutions of test agents were prepared fresh as mg=ml or molar solutions for in vivo and in vitro experiments, respectively. For test agents used in apomorphine erection experiments all drugs except CGS12066b were dissolved in distilled water. CGS12066b was dissolved in 0.5% 0.1 N HCl. The CGS12066b solvent also served as a vehicle for control test groups. For cavernous nerve studies all drugs were dissolved in distilled water. For in vitro experiments stock solutions were made in saline at 10 72 M with dilution to appropriate concentrations.
Data recording and analysis
In experiments involving drug actions on cavernous nerve and intracavernous pressure responses all data was recorded at 200 samples=second on a MacIntosh computer using MacLab analog-digital conversion (ADI Instruments, Australia). Low frequency in vitro experiments were also recorded by MacLab. Results from studies involving apomorphine-induced erection were analyzed, by ANOVA with Dunnett's test for multiple comparisons for significant differences between test animals receiving only vehicle and test animals receiving vehicle or test drug followed by apomorphine.
For experiments involving cavernous nerve activity and intracavernous pressure responses group mean data for blood pressure and intracavernous pressure responses were compared by ANOVA with Dunnett's test for multiple comparisons. ANOVA was used to compare intracavernous pressure responses within treatment groups. Mainlands contingency tables were used to compare the number of animals exhibiting CNA. 16 In all cases P < 0.05 was taken as a significant result.
Drug effects on rabbit CC in vitro were compared using ANOVA or t-tests for differences between drug treatment and a saline control. In all cases P < 0.05 was taken as a significant result. Curves were fit using a logistic function of the form response ¼ constant þ maximal effect=(1 þ (concentration=ED 50 n ). ED 50 and EF 50 estimates and 95% confidence intervals were derived from the computer generated curve fits. Table 1 ). The apomorphine induced erectile response was significantly reduced by the highest two doses of the 5HT 1a agonist 8-OHDPAT (0.04 -0.64 mg=kg) and by all doses of the 5HT 1b agonist CGS12066b (1.0 -10.0 mg=kg) ( Table 1) . At the highest doses tested both 8-OHDPAT and CGS12066b reduced apomorphine erectile responses to 0.9 AE 0.2 erections and 0.5 AE 0.3 erections, respectively. This level of erectile response was not significantly different from vehicle treated control animals.
Cavernous nerve and intracavernosal pressure responses in rats in vivo m-CPP caused characteristic changes in blood pressure, cavernous nerve and intracavernous pressure responses. Intravenous administration of m-CPP caused an increase in mean blood pressure of þ 25.6 AE 6.5 mmHg and induced CNA in 8=8 test animals (Figures 2 and 3) . Nerve responses occurred prior to significant increases in intracavernous pressure of þ 37.6 AE 9.1 mmHg (Figure 3 ). Increases in ICP were not coincident with maximal increases in blood pressure. Thirty minutes after m-CPP administration the ICP response to direct nerve stimulation were still intact with increases in ICP of þ 34.0 AE 7.0 mmHg ( Table 2) . m-CPP attenuated its own ability to elicit CN and ICP responses. The m-CPP test dose failed to induce CN responses in rats treated previously with m-CPP (see Figure 1) . In the presence of m-CPP, the m-CPP test dose resulted in ICP responses of only þ 10.9 AE 2.1 mmHg (Figure 4) . Restimulation of the CN resulted in significant ICP responses of þ 31.8 AE 8.4 mmHg even after challenge with the m-CPP test dose ( Table 2) .
8-OHDPAT and CGS12066b produced different effects on blood pressure. 8-OHDPAT increased blood pressure by þ 18 AE 11.6 mmHg whereas CGS12066b reduced mean blood pressure by 7 25 AE 4.7 mmHg. 8-OHDPAT and CGS12066b both failed to induce CN or ICP responses similar to m-CPP ( Figure 3 ). Mean changes in ICP were þ 9.3 AE 1.7 mmHg, þ 7.7 AE 2.9 mmHg and þ 13.5 AE Indicates a significant difference (P < 0.05) from predrug values within a treatment group as determined by ANOVA. The frequency for half-maximal relaxation [EF 50 (95% CI)] of NA induced tone in saline treated CC strips was 10.3 Hz (6.2 -14.5 Hz). CGS12066b (10 76 M) failed to alter NANC mediated relaxation of CC strips with an EF 50 estimate of 8.5 Hz (7.9 -9.2 Hz) (data not shown). 8-OHDPAT was without effect on NANC relaxation responses to submaximal EFS at 8 Hz (data not shown). Relaxation responses to 8 Hz EFS were 35 AE 8%, 31 AE 7%, 31 AE 6% and 37 AE 5% prior to the administration of saline or 8-OHDPAT at 10 78 M, 10 76 M and 10 74 M, respectively. Following drug treatment responses were unchanged at 40 AE 9%, 33 AE 8%, 34 AE 6% and 32 AE 4% respectively.
Discussion
The main findings of the present study were that: (a) Erection induced by the subcutaneous administration of apomorphine has been described as a useful model of 'psychogenic' erection that closely parallels the erectile responses of sexually experienced test animals in copula. 17 -19 Our results confirm previous findings of the inhibitory nature of 5-HT 1a receptor activation on erection mediated by dopamine agonists. 8 The inhibitory actions of 8-OHDPAT on dopamine and 5-HT 2c agonist-induced erection are believed to result from actions at postsynaptic sites upstream from a final cholinergic link. 9 Previous reports have shown that CGS12066b does not elicit erection in conscious rats and fails to alter 5-HT 2c mediated increases in erection. 8 However, in the present study CGS12066b completely prevented the erectile responses resulting from apomorphine administration. The mechanism for this inhibitory action was not defined in the present study. However, previous work has shown that 5-HT 1b receptors may modulate other monaminergic and cholinergic synapses, 20 and that the apomorphine induced erectile response is dependent on a functional cholinergic system. 10 Therefore, it is possible that 5-HT 1b agonists may act to inhibit the apomorphine-induced erectile response downstream from dopaminergic centers at sites that are not required for 5-HT 2c agonist-mediated expression of erection.
Previously, Steers and De Groat 6 reported that CN and ICP responses elicited by m-CPP were mediated by activation of preganglionic autonomic nerves, and=or postsynaptic 5-HT 1b receptors as the m-CPP response was blocked by the non-selective 5-HT antagonist metergoline but not by transection of the spinal cord. 8-OHDPAT and CGS12066b lacked the ability to induce activity in the cavernous nerve or increases in intracavernosal pressure similar to m-CPP. Therefore, the present findings suggest that the nerve and pressure responses resulting from m-CPP administration are not mediated by activation of 5HT 1a or 5HT 1b receptors.
A very interesting finding of the present study was the differential effects of the 5-HT 1a and 5-HT 1b agonists on nerve and pressure responses to m-CPP administration. 8-OHDPAT dramatically enhanced the ICP response whereas CGS12066b clearly inhibited the ICP response. CGS12066b is a piperazine and 8-OHDPAT is an aminotetralin. Therefore, it is possible that the piperazines act as antagonists of the m-CPP response through an as yet undefined mechanism. The fact that m-CPP (also a piperazine) antagonizes its own effects (present study) and leads to long-term desensitization of the response 6 also lend support to this idea.
Previous work has demonstrated that central and systemic administration of 8-OHDPAT causes a reduction in ejaculatory threshold. 21, 22 The results of the present study indicate that the m-CPP induced CN and ICP responses may be closely related to CN and ICP responses in copula. 8-OHDPAT failed to significantly alter intracavernous pressure responses mediated by direct stimulation of the cavernous nerve. Therefore, in agreement with the attenuation of the apomorphine induced erectile responses and facilitation of the m-CPP CN and ICP response, 5-HT 1a receptor activation does not appear to inhibit erectile function arising from direct stimulation of the cavernous nerve but does inhibit central mechanisms of erection which are ultimately dependent on activation of the cavernous nerve. CGS12066b inhibited apomorphine-induced erection, CN and ICP responses caused by m-CPP and ICP responses resulting from direct stimulation of the CN. These results suggest that, unlike 5-HT 1a agonists, 5-HT 1b agonists may act at sites both proximal and distal to the cavernous nerve to inhibit erection.
As the compounds tested in the present study clearly had similar actions on central mechanisms and different actions on peripheral mechanisms of erection it was desirable to determine if they had direct actions on corporal smooth muscle. 8-OHD-PAT and CGS12066b failed to alter the contractile responses of rabbit corporal smooth muscle to noradrenaline, actions that are in agreement with their selectivity for 5-HT receptors over adrenergic receptors. 23 Both compounds also failed to alter NANC mediated relaxation elicited by electrical stimulation of corporal tissue. These results suggest 
Conclusions
The 5-HT 1a (8-OHDPAT) and 5-HT 1b (CGS12066b) agonists dose-dependently inhibited erection induced by apomorphine, effects that may not be attributed to anti-erectile actions on corporal smooth muscle. Although 8-OHDPAT and CGS12066b were unable to elicit increases in cavernous nerve activity and intracavernous pressure, 8-OHDPAT potentiated cavernous nerve and intracavernous pressure responses elicited by m-CPP whereas CGS12066b attenuated m-CPP induced responses. Therefore 5-HT 1a agonists act centrally to inhibit dopaminergic mediated erection but may also act to enhance erectile responses produced by direct stimulation of peripheral nerves. CGS12066b attenuated m-CPP induced increases in cavernous nerve activity and intracavernous pressure responses thus suggesting 5-HT 1b receptors, and not 5-HT 1d receptors as previously suspected, may be responsible for the desensitization of the m-CPP response. The different effects of 5-HT 1a and 5-HT 1b agonists on erection resulting from direct stimulation of the cavernous nerve may not be explained by differential effects on corporal smooth muscle tone. These results suggest that compounds which indiscriminantly increase the availability of 5-HT at all 5-HT receptors (SSRI's and 5-HT releasers) will have complex effects on erection and sexual function. Furthermore, selective 5-HT 1a and 5-HT 1b agonists developed for treatment of disorders such as obesity, 24 migraine 25 and anxiety 26 may have an impact on erectile function in humans.
